Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases

Area of Science:

• Epigenetics and Molecular Biology
• Cancer Research and Pharmacology

Background:

• Aberrant chromatin structure and dynamics are implicated in human malignancies.
• Histone lysine methylation, regulated by histone lysine methyltransferases (KMTs) and demethylases (KDMs), is crucial in disease pathogenesis.
• Dysregulation of KMT and KDM activity is linked to various human diseases.

Purpose of the Study:

• To critically evaluate the development and optimization of small molecule inhibitors targeting histone KMTs and KDMs.
• To highlight the role of structural biology in advancing epigenetic drug discovery.
• To explore therapeutic interventions for diseases driven by aberrant epigenetic modifications.

Main Methods:

• Review and critical evaluation of current research on small molecule inhibitors for KMTs and KDMs.
• Emphasis on structure-based drug design principles.
• Analysis of contributions from structural biology to epigenetic drug development.

Main Results:

• Significant progress has been made in developing potent small molecule inhibitors for histone KMTs and KDMs.
• Structural biology insights have been pivotal in optimizing inhibitor potency and specificity.
• Targeting these epigenetic enzymes represents a viable pharmacological strategy.

Conclusions:

• Small molecule inhibitors targeting KMTs and KDMs are promising therapeutic agents for epigenetic-driven diseases.
• Continued advances in epigenetic inhibitor development are expected to yield novel drugs.
• Future drugs will likely offer site-specific targeting of KMTs and KDMs for precise epigenetic landscape modulation.